ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I
MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other oncology drugs.
MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other oncology drugs.
What's Your Reaction?
